Results 201 to 210 of about 139,089 (266)

Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. [PDF]

Curr Oncol
Dai KY, Chen FY, Liu CK, Lin J, Liu SH.
europepmc   +1 more source

Correction: Synthesis, characterization, DNA interaction, and anticancer studies of novel <i>facial</i> tricarbonylrhenium(i) complexes with uracil-derived ligands. [PDF]

RSC Adv
Abdullah S, Davison C, Smit CJ, Mbatha P, de la Mare JA, Booysen IN.   +5 more
europepmc   +1 more source

Gim3 buffers and potentiates de novo mutations that affect fluconazole susceptibility in yeast. [PDF]

EMBO Rep
Tawfeeq MT, Konstantinidis D, Rocha Iraizos AL, Van Genechten W, Vreys J, Vermeersch L, Voordeckers K, Van Dijck P, Verstrepen KJ.   +8 more
europepmc   +1 more source

Pathological Response of Locally Recurrent Rectal Cancer to Neoadjuvant Chemoradiotherapy. [PDF]

J Anus Rectum Colon
Yokoyama Y, Ozaki K, Nozawa H, Sasaki K, Murono K, Emoto S, Kaneko K, Matsuzaki H, Abe S, Nagai Y, Shinagawa T, Ishihara S.   +11 more
europepmc   +1 more source

Development of a markerless tool for targeted chromosome modification in the thermophilic and methylotrophic bacterium Bacillus methanolicus. [PDF]

Microb Cell Fact
Irla M, Brito LF, Langlo J, Wohlers C, Benninghaus L, Heid C, Wendisch VF, Schmid J, Brautaset T.   +8 more
europepmc   +1 more source

Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis. [PDF]

Life (Basel)
Cheng MC, Lee HL, Lai SW, Chen JH, Chen PH.   +4 more
europepmc   +1 more source

Bridging mechanism and design: modern medicinal chemistry approaches to thymidylate synthase inhibitors. [PDF]

RSC Adv
Al-Karmalawy AA, Eissa ME, Yousef TA, Al Khatib AO, Hawas SS.   +4 more
europepmc   +1 more source

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial. [PDF]

RMD Open
Gavin PG, Allman EL, Jayne D, Mysler E, Amoura Z, Di Poto C, Tian X, Hess S, Csomor E, Brohawn PZ, Muthas D, Platt A, Anzillotti C, Stone H, Seth A, Woollard K, Al-Mossawi H, Lindholm C, Ferrari N.   +18 more
europepmc   +1 more source